4DMedical has inked a deal to acquire Imbio, a company backed by Invenshure, to enhance its lung imaging technologies. This acquisition aligns with 4DMedical’s goal of improving respiratory imaging and ventilation, offering quantitative and personalized analysis for patients with lung diseases, and strengthening its position in lung disease detection and management.

4DMedical XV Technology current and pipeline software products provide regional quantification of lung function using existing imaging equipment, or the dedicated XV Scanner. Imbio’s fully automated technology transforms chest CT studies into rich visual maps of a patient’s lungs. 

Accompanying reports provide detailed data on the type and extent of abnormalities found in the images. Imbio algorithms support multiple clinical initiatives such as lung cancer screening, smoking cessation, surgical planning, and pulmonary embolism management programs—and can be used in clinical trials and academic research for numerous diseases.

The combined technology offering can turn any standard chest CT into a much broader crdiothoracic analysis—providing functional, structural, and risk-based analysis for both lung and heart disease.

4DMedical’s launch of XV Technology in the U.S. will leverage existing Imbio contracts, allowing for patient screening programs in Australia and the U.S. for conditions like chronic obstructive pulmonary disease, interstitial lung disease, lung cancer, and heart disease.

4DMedical Founder and CEO Andreas Fouras, PhD, says, “Imbio’s suite of products deploy AI solutions to add quantification and visualization to lung structure from CT scans, bringing new indications to 4DMedical. The acquisition also provides additional inroads to engage with the U.S. Department of Veterans Affairs, boosting 4DMedical’s mission to improve healthcare for veterans.”

“Imbio is very excited to join forces with 4DMedical to offer expanded capabilities and customer support. Together, we can help clinicians utilize the vast quantitative information obtained from patients’ diagnostic chest images for lung pathologies to ultimately drive actionable decision-making for better patient care,” adds Dave Hannes, CEO at Imbio.